Can produce 250 mn doses of Sputnik V every year: Morepen India CMD

The approval of samples, licensing, and final production will take around two months and the vaccine would be available in India for sale also in two months, says CMD Sushil Suri

Morepen India Chairman and Managing Director Sushil Suri in an interview with Uddalok Bhattacharya says the Sputnik V vaccine the firm is manufacturing in India will be available in the market in two months. Besides, the company is working on other fronts such as monoclonal antibodies to treat Covid and its variants. Edited excerpts:

Can you throw light on the recent development about your tie-up for manufacturing the Sputnik vaccine in India?

The Russian Direct Investment Fund (RDIF) has an agreement with Morepen to manufacture Sputnik V in India and has started the technology transfer process. We have taken test